SES Logo

SYSTEMIC ENZYME SUPPORT.org

 

Autoimmune Thyroid Disease

Wobenzym® significantly improves autoimmune hypothyroidism (Hashimoto’s), the most common cause of hypothyroidism. Autoimmune hypothyroidism is a condition that until now has been somewhat difficult to successfully treat due to the chronic inflammation taking place in that condition. Even after the patient’s hormone levels have been brought back to normal with prescription thyroid replacement, we still see many clinical signs of hypothyroidism.
Autoimmune hypothyroidism (Hashimoto’s) – the most common cause of hypothyroidism - is a condition that can be somewhat difficult to successfully treat due to the chronic inflammation taking place in that condition. Even after the patient’s hormone levels have been brought back to normal with prescription thyroid replacement, we still see many clinical signs of hypothyroidism.
For instance, even after thyroid replacement therapy (TRT), patients can still have elevated cholesterol and triglycerides. However, when TRT patients that still had elevated cholesterol and triglycerides were  given 5 Wobenzym® tablets, 3 times a day their cholesterol and triglycerides decreased. The patients that were only given thyroid replacement still had elevated cholesterol and triglycerides.
We also noted that taking Wobenzym® resulted in a reduction of autoimmune antibodies that attack the thyroid – the anti-TG and anti-TPO antibodies. With the reduced antibodies, the thyroid is no longer under attack from the immune system, and is able to resume making thyroid hormones that way that it should.
Patients on Wobenzym® also showed a reduction of TSH levels – which is due to increased function of thyroid hormones. As a result, patients that received Wobenzym® as part of their therapy were able to lower their dosage of thyroid medication after 3 months, or completely discontinue the thyroid medication in some cases.
Based on what we now know, I would say that this is possible because of the beneficial effect that Wobenzym® has on the hypothalamic-pituitary-thyroid axis, its effect on the thyroid tissue itself,  and its effect on the immune system - the elimination of autoimmune destruction of the thyroid.
The pro-inflammatory cytokines that we see in both autoimmune disease and in systemic inflammation have a very detrimental effect on thyroid function on so many levels. If we keep in mind that the first word in the phrase “autoimmune thyroid disease” is “autoimmune” we will have a better understanding of why the immunomodulation properties of Wobenzym® are so effective in treating autoimmune hypothyroidism.

                             From FREQUENTLY ASKED QUESTIONS, with answers by Joseph J Collins, RN, ND
                             Read the special section: HORMONES & WOBENZYM®

 

What the literature says about Systemic Enzyme Support and:

Autoimmune Thyroid Disease

Wobenzym in the complex treatment of autoimmune thyroiditis.  

Kvantchakhadze R.G. Wobenzym in the complex treatment of autoimmune thyroiditis. International Journal on Immunorehabilitation, 2002,  Vol. 4, No. 1, pp. 114. [Czech abstract, Russian abstract] Research and Therapeutic Center of Rheumatology, Tbilisi, Gruzia. VIII. International Congress on Immunorehabilitation „Allergy, Immunology, and Global Net“, April 21-24, 2002, Cannes, France  

40 patients suffering from autoimmune thyroiditis were observed for 6 months. Patients were divided into two groups. 20 patients in the group I were treated depending on thyroid condition (euthyreosis, hypothyreosis) with L-tyroxin (25 – 100 mg daily) in combination with Wobenzym (5 coated tablets three times a day). Patients in the group II were treated with L-tyroxin only at the above dosage.
Both groups were comparable with regard to age, sex, and clinical-laboratory parameters. All usual parameters were examined before treatment, after 1 and 3 months, and at the end of treatment.  Improvement of thyroid parameters at ultrasound examination (reduction of size, improved tissue structure) and aspiration biopsy parameters (reduced number of lymphoid and plasmocytoma cells in cytologic punctuate) as well as significant decrease of blood thyreotropin level and titers of antibodies against thyreoglobulin and microsomal fraction accompanied by the improvement of subjective parameters were found in the group I after 3 months of treatment, whereas in the group II after 6 months of treatment. In both groups of patients suffering from hypothyreosis, an impaired lipid metabolism was found.
Treatment of patients in the group I resulted in a decrease of cholesterol and triglyceride levels, whereas in patients in the group II there were no significant changes found during the treatment.
In patients in the group I dosage of L-tyroxin could be lowered after 3 months of treatment, in some cases it could even be discontinued. Under continuous Wobenzym treatment improved clinical-laboratory parameters were maintained. Thus, Wobenzym was shown to be therapeutically effective in a complex therapy of autoimmune thyroiditis.
Poster Reference Number 50.